TriLink BioTechnologies® and the International Vaccine Institute Sign a Memorandum of Understanding to Support the Development of mRNA-based Vaccines
Dr. Jerome Kim, Director General of IVI (left), standing next to TriLink’s Chief Commercial Officer, Becky Buzzeo, after signing the 'Memorandum of Understanding to Support the Development of mRNA-based Vaccines.'
According to the terms of the MOU, TriLink and IVI will enter discussions on collaborative models to develop vaccines using mRNA technologies, facilitate knowledge exchange, and support joint scientific initiatives.
"This collaboration will not only advance the science of mRNA-based vaccines but may also significantly enhance access to life-saving vaccines in low- and middle-income countries (LMICs),” said Maravai and TriLink’s Chief Commercial Officer, Becky Buzzeo. “By combining our expertise in nucleic acids with the International Vaccine Institute's global reach and commitment to public health, we are poised to profoundly impact global health equity. Together, we can accelerate the development and distribution of innovative mRNA vaccines, ensuring that more people, regardless of their geographic location, have access to the critical healthcare they need."
Since its launch in 2017, TriLink’s CleanCap® capping technology has continued to advance the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines. In 2024, TriLink expanded its products and services specifically for customers working in mRNA therapeutics, launching IVT enzymes, including CleanScribe™ RNA polymerase, which has been shown to reduce dsRNA, and opened its commercially ready GMP manufacturing facility in
IVI, based in
“IVI is pleased to partner with TriLink BioTechnologies, a leading provider of life science reagents and services, including its proprietary capping technology that enhances mRNA stability and translation efficiency,” said Dr. Jerome Kim, Director General of IVI. “This collaboration will empower the two organizations and our partners to accelerate the development and global delivery of advanced mRNA vaccines, especially to people in LMICs.”
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders to enabling future pandemic response plans.
For more information, visit trilinkbiotech.com
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit maravai.com
About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.
IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that also achieved WHO prequalification in early 2024.
IVI is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250514331075/en/
Media contact:
Liz Robinson of CG Life
TriLink BioTechnologies
+1 312-997-2436
lrobinson@cglife.com
Investor contact:
Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com
Aerie Em, Global Communications & Advocacy Manager
+82 2 881 1386 | aerie.em@ivi.int
Tae Kyung Byun, Head of Government and Public Relations (
+82 2 881 1159 | tkbyun@ivi.int
Source: TriLink BioTechnologies
